TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 255 filers reported holding TG THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $880,015 | +345.6% | 36,500 | +170.4% | 0.00% | – |
| Q1 2023 | $197,505 | +68.8% | 13,500 | +11.8% | 0.00% | – |
| Q1 2022 | $117,000 | -70.7% | 12,080 | +1.6% | 0.00% | – |
| Q3 2021 | $399,000 | +18.0% | 11,892 | +37.2% | 0.00% | – |
| Q2 2021 | $338,000 | -72.3% | 8,666 | -65.7% | 0.00% | -100.0% |
| Q1 2021 | $1,220,000 | -66.1% | 25,300 | -63.4% | 0.00% | -80.0% |
| Q4 2020 | $3,600,000 | +205.9% | 69,200 | +57.3% | 0.01% | +150.0% |
| Q3 2020 | $1,177,000 | +51.1% | 44,000 | +10.0% | 0.00% | +100.0% |
| Q2 2020 | $779,000 | -33.1% | 40,000 | -62.5% | 0.00% | -50.0% |
| Q4 2019 | $1,164,000 | +802.3% | 106,691 | +363.9% | 0.00% | – |
| Q3 2019 | $129,000 | -52.2% | 23,000 | -26.4% | 0.00% | – |
| Q2 2019 | $270,000 | +13.0% | 31,229 | +4.9% | 0.00% | – |
| Q1 2019 | $239,000 | +20.7% | 29,761 | -16.0% | 0.00% | – |
| Q3 2018 | $198,000 | -55.9% | 35,425 | +3.5% | 0.00% | -100.0% |
| Q2 2018 | $449,000 | – | 34,239 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,890,000 | $15,800,400 | 5.14% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,360,000 | 2.75% |
| Soleus Capital Management, L.P. | 2,884,382 | $24,113,434 | 2.22% |
| M28 Capital Management LP | 216,600 | $1,810,776 | 2.08% |
| Paradigm Biocapital Advisors LP | 3,619,015 | $30,254,965 | 2.05% |
| 683 Capital Management, LLC | 1,350,000 | $11,286,000 | 0.88% |
| Parkwood LLC | 165,414 | $6,081 | 0.66% |
| Spotlight Asset Group, Inc. | 79,000 | $660,440 | 0.60% |
| Pier Capital, LLC | 392,709 | $3,283,047 | 0.53% |
| Quantum Private Wealth, LLC | 91,081 | $761,438 | 0.36% |